3,5-二乙基苯甲酸 | 3854-90-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3,5-二乙基苯甲酸
• 英文名称: 3,5-diethylbenzoic acid
• CAS: 3854-90-8
• 化学式: C₁₁H₁₄O₂
• mdl: MFCD09743750
• 分子量: 178.231
• InChiKey: MSWNGSGXXVLVPG-UHFFFAOYSA-N

物化性质

• 熔点：
  133 °C
• 沸点：
  307.0±31.0 °C(Predicted)
• 密度：
  1.063±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.363
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2916399090

反应信息

• 作为反应物：
  描述：

  3,5-二乙基苯甲酸 在 lithium aluminium tetrahydride 、 氯化亚砜 作用下， 以 四氢呋喃 为溶剂， 反应 6.0h， 生成 (3,5-Diethyl-phenyl)-acetonitrile
  参考文献：
  名称：

  Discovery and structure-activity studies of a novel series of pyrido[2,3-d]pyrimidine tyrosine kinase inhibitors

  摘要：

  The inhibition of tyrosine kinase-mediated signal transduction pathways represents a therapeutic approach to the intervention of proliferative diseases such as cancer, atherosclerosis, and restenosis. A novel series of pyrido[2,3-d]pyrimidine inhibitors of the PDGFr, bFGFr, and c-Src tyrosine kinases was developed from compound library screening and lead optimization.(1) In addition, highly selective inhibitors of the FGFr tyrosine kinase were also discovered and developed from this novel series of pyrido[2,3-d]pyrimidines. The syntheses, biological evaluation, and structure-activity relationships of this series are reported. (C) 1997 Elsevier Science Ltd.

  DOI：

  10.1016/s0960-894x(97)00445-9
• 作为产物：
  描述：

  1,3,5-三乙基苯 在 sodium hydroxide 、 N-溴代丁二酰亚胺(NBS) 、 jones reagent 、 溴 、 barium carbonate 作用下， 以 1,4-二氧六环 、 四氯化碳 、 水 、 丙酮 为溶剂， 生成 3,5-二乙基苯甲酸
  参考文献：
  名称：

  Discovery and structure-activity studies of a novel series of pyrido[2,3-d]pyrimidine tyrosine kinase inhibitors

  摘要：

  The inhibition of tyrosine kinase-mediated signal transduction pathways represents a therapeutic approach to the intervention of proliferative diseases such as cancer, atherosclerosis, and restenosis. A novel series of pyrido[2,3-d]pyrimidine inhibitors of the PDGFr, bFGFr, and c-Src tyrosine kinases was developed from compound library screening and lead optimization.(1) In addition, highly selective inhibitors of the FGFr tyrosine kinase were also discovered and developed from this novel series of pyrido[2,3-d]pyrimidines. The syntheses, biological evaluation, and structure-activity relationships of this series are reported. (C) 1997 Elsevier Science Ltd.

  DOI：

  10.1016/s0960-894x(97)00445-9

文献信息

• Base- and Additive-Free Ir-Catalyzed <i>ortho</i>-Iodination of Benzoic Acids: Scope and Mechanistic Investigations
  作者：Elis Erbing、Amparo Sanz-Marco、Ana Vázquez-Romero、Jesper Malmberg、Magnus J. Johansson、Enrique Gómez-Bengoa、Belén Martín-Matute

  DOI：10.1021/acscatal.7b02987

  日期：2018.2.2

  A protocol for the C–H activation/iodination of benzoic acids catalyzed by a simple iridium complex has been developed. The method described in this paper allows the ortho-selective iodination of a variety of benzoic acids under extraordinarily mild conditions in the absence of any additive or base in 1,1,1,3,3,3-hexafluoroisopropanol as the solvent. The iridium catalyst used tolerates air and moisture

  已经开发了一种由简单铱络合物催化的苯甲酸的C–H活化/碘化的方案。本文描述的方法允许在非常温和的条件下，在没有任何添加剂或碱的情况下，在1,1,1,3,3,3-六氟异丙醇作为溶剂中对多种苯甲酸进行邻位碘化。所用的铱催化剂可耐受空气和湿气，并选择性地以高转化率得到邻碘苯甲酸。机理研究表明，Ir（III）/ Ir（V）催化循环起作用，并且HFIP的独特性质使得能够使用羧基作为引导基团进行C-H碘化。
• Attenuation of London Dispersion in Dichloromethane Solutions
  作者：Robert Pollice、Marek Bot、Ilia J. Kobylianskii、Ilya Shenderovich、Peter Chen

  DOI：10.1021/jacs.7b06997

  日期：2017.9.20

  London dispersion constitutes one of the fundamental interaction forces between atoms and between molecules. While modern computational methods have been developed to describe the strength of dispersive interactions in the gas phase properly, the importance of inter- and intramolecular dispersion in solution remains yet to be fully understood because experimental data are still sparse in that regard

  伦敦色散构成原子之间以及分子之间基本相互作用力之一。尽管已经开发出现代计算方法来恰当地描述气相中分散相互作用的强度，但是溶液中分子间和分子内分散的重要性仍有待充分理解，因为在这方面实验数据仍然很少。我们在本文中报告了伦敦分散体在气相和二氯甲烷溶液中对质子结合的二聚体的键解离的贡献的详细实验和计算研究，表明溶剂对分子间和分子内分散相互作用的衰减很大（约70％的二氯甲烷），但不完整，
• [EN] HETEROCYCLIC CHROMENE-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS<br/>[FR] AMIDES DE CHROMÈNE HÉTÉROCYCLIQUE-PIPÉRIDINE SPIROCYCLIQUE UTILES COMME MODULATEURS DES CANAUX IONIQUES
  申请人：VERTEX PHARMA

  公开号：WO2011140425A1

  公开（公告）日：2011-11-10

  The invention relates to heterocyclic chromene-spirocyclic piperidine amides useful as inhibitors of ion channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.

  本发明涉及杂环色烯-螺环哌啶酰胺，用作离子通道的抑制剂。本发明还提供了包含本发明化合物的药用可接受组合物，以及使用这些组合物治疗各种疾病的方法。
• [EN] CYTOTOXIC BIS-BENZODIAZEPINE DERIVATIVES AND CONJUGATES THEREOF WITH CELL-BINDING AGENTS FOR INHIBITING ABNORMAL CELL GROWTH OR FOR TREATING PROLIFERATIVE DISEASES<br/>[FR] DÉRIVÉS DE BIS-BENZODIAZÉPINE CYTOTOXIQUES ET LEURS CONJUGUÉS AVEC DES AGENTS DE LIAISON À UNE CELLULE POUR INHIBER LA CROISSANCE CELLULAIRE ANORMALE OU POUR TRAITER DES MALADIES PROLIFÉRATIVES
  申请人：IMMUNOGEN INC

  公开号：WO2020205564A1

  公开（公告）日：2020-10-08

  The invention relates to benzodiazepine derivatives with antiproliferative activity and more specifically to benzodiazepine compounds of formulae (I), (II), (TI) and (T2). The invention also provides conjugates of the benzodiazepine compounds linked to a cell-binding agent. The invention further provides compositions and methods for inhibiting abnormal cell growth or treating a proliferative disorder in a mammal using the compounds or conjugates of the invention.

  这项发明涉及具有抗增殖活性的苯二氮䓬啶衍生物，更具体地涉及具有式(I)、(II)、(TI)和(T2)的苯二氮䓬啶化合物。该发明还提供了与细胞结合剂连接的苯二氮䓬啶化合物的结合物。该发明还提供了使用该发明的化合物或结合物抑制异常细胞生长或治疗哺乳动物增殖性疾病的组合物和方法。
• METHODS OF MODULATING NEUROTROPHIN-MEDIATED ACTIVITY
  申请人：VOHRA Rahul

  公开号：US20090082368A1

  公开（公告）日：2009-03-26

  Disclosed are compositions which modulate the interaction with nerve growth factor and precursors thereof with neurotrophic receptors. Also disclosed are methods of using the compositions of the invention, including methods of administration.

  揭示了一种调节神经生长因子及其前体与神经营养受体相互作用的组合物。还揭示了使用该发明的组合物的方法，包括给药方法。